Trial · NCT00657150
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period | Dabigatran 220mg | 61 | Participants | ||
| Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period | Enoxaparin | 69 | Participants | ||
| Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period | Dabigatran 220mg | 18 | Participants | ||
| Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period | Enoxaparin | 33 | Participants | ||
| Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period | Dabigatran 220mg | 17 | Participants | ||
| Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period | Enoxaparin | 31 | Participants | ||
| Number of Participants With Total Deep Vein Thrombosis During Treatment Period | Dabigatran 220mg | 60 | Participants | ||
| Number of Participants With Total Deep Vein Thrombosis During Treatment Period | Enoxaparin | 67 | Participants | ||
| Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period | Dabigatran 220mg | 0 | Participants | ||
| Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period | Enoxaparin | 4 | Participants | ||
| Number of Participants With Pulmonary Embolism During Treatment Period | Dabigatran 220mg | 1 | Participants | ||
| Number of Participants With Pulmonary Embolism During Treatment Period | Enoxaparin | 2 | Participants | ||
| Number of Participants Who Died During Treatment Period | Dabigatran 220mg | 0 | Participants | ||
| Number of Participants Who Died During Treatment Period | Enoxaparin | 1 | Participants | ||
| Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | Dabigatran 220mg | Total VTE and all-cause mortality | 2 | Participants | |
| Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | Enoxaparin | Total VTE and all-cause mortality | 4 | Participants | |
| Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | Dabigatran 220mg | asymptomatic Deep Vein Thrombosis | 0 | Participants | |
| Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | Enoxaparin | asymptomatic Deep Vein Thrombosis | 1 | Participants | |
| Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | Dabigatran 220mg | symptomatic Deep Vein Thrombosis | 1 | Participants | |
| Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period | Enoxaparin | symptomatic Deep Vein Thrombosis | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00657150/results